Valuation: Novo Nordisk A/S

Capitalization 1,330B 210B 178B 163B 154B 287B 19,975B 289B 1,932B 754B 9,513B 787B 770B 32,921B P/E ratio 2026 *
13.6x
P/E ratio 2027 * 14.1x
Enterprise value 1,446B 228B 193B 177B 167B 312B 21,717B 314B 2,101B 820B 10,343B 855B 837B 35,793B EV / Sales 2026 *
4.97x
EV / Sales 2027 * 4.83x
Free-Float
71.44%
Yield 2026 *
3.72%
Yield 2027 * 3.63%
1 day+0.85%
1 week+5.68%
Current month+10.98%
1 month+26.82%
3 months-1.44%
6 months-5.89%
Current year-7.10%
1 week 287
Extreme 287
312.05
1 month 235.95
Extreme 235.95
312.05
Current year 224.25
Extreme 224.25
409.95
1 year 224.25
Extreme 224.25
533.4
3 years 224.25
Extreme 224.25
1,033.2
5 years 224.25
Extreme 224.25
1,033.2
10 years 109.1
Extreme 109.1
1,033.2
Manager TitleAgeSince
Chief Executive Officer 56 07/08/2025
Director of Finance/CFO 55 15/02/2018
Chief Tech/Sci/R&D Officer 56 07/08/2025
Director TitleAgeSince
Director/Board Member 61 23/03/2017
Director/Board Member 51 22/03/2018
Director/Board Member 61 24/03/2022
Change 5d. change 1-year change 3-years change Capi.($)
+0.84%+5.68%-31.55%-48.60% 210B
+1.95%-0.10%+31.64%+122.02% 862B
+0.05%-1.24%+43.58%+37.54% 533B
+0.61%-2.58%+9.85%+38.33% 358B
+1.06%-0.38%+22.40%+11.63% 328B
-0.65%+0.74%+30.72%+11.81% 286B
+0.32%+0.37%+24.30%+23.16% 279B
-0.09%-1.62%+46.48%-5.33% 275B
-0.64%+1.77%+23.97%+41.89% 178B
+1.67%+0.63%+37.78%+69.66% 166B
Average +0.34%+0.10%+23.92%+30.21% 347.46B
Weighted average by Cap. +0.28%-0.38%+26.95%+46.04%

Financials

2026 *2027 *
Net sales 291B 45.91B 38.96B 35.68B 33.64B 62.74B 4,374B 63.25B 423B 165B 2,083B 172B 169B 7,209B 299B 47.06B 39.94B 36.58B 34.49B 64.32B 4,484B 64.84B 434B 169B 2,135B 177B 173B 7,390B
Net income 97.23B 15.33B 13.01B 11.91B 11.23B 20.95B 1,460B 21.12B 141B 55.15B 696B 57.52B 56.31B 2,407B 95.11B 14.99B 12.72B 11.65B 10.99B 20.49B 1,429B 20.66B 138B 53.94B 680B 56.26B 55.08B 2,355B
Net Debt 116B 18.29B 15.52B 14.21B 13.4B 25B 1,743B 25.2B 169B 65.79B 830B 68.62B 67.18B 2,872B 113B 17.78B 15.09B 13.82B 13.03B 24.31B 1,694B 24.5B 164B 63.98B 807B 66.73B 65.33B 2,793B
Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.7%); - rare disease treatment products (6.3%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe and Canada (21.4%), the United States (56%), Latin America/Middle East/Africa (9.9%), China/Hong Kong/Taiwan (6%), Asia/Pacific (6.7%).
Employees
67,900
Date Price Change Volume
12/05/26 302.05 kr +0.68% 1,564,143
11/05/26 300.00 kr +3.34% 7,278,350
08/05/26 290.30 kr -1.76% 4,614,317
07/05/26 295.50 kr +0.85% 5,530,016
06/05/26 293.00 kr +2.48% 15,205,850
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
300.00DKK
Average target price
307.99DKK
Spread / Average Target
+2.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NOVO B Stock